Protecting The CNS Signal: Site-Level Patient Selection That Separates Drug From Placebo

Most CNS programs that fail do not fail on biology. They fail because active treatment never separates from placebo. This session, timed to the neuroscience field's flagship leadership meeting, shows how patient selection, referral pathways, assessment consistency, and retention at the site protect the signal a sponsor paid to detect.

LEARNING OBJECTIVES
- Locate the site-level decisions that raise or lower placebo response.
- Evaluate referral pathways that confirm diagnosis before screening.
- Build a CNS site checklist covering selection, consistency, and retention.